# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION MEMORANDUM

A. 510(k) Number: K162788   
B. Purpose for Submission: New device   
C. Measurand: IgA autoantibodies specific for $\beta _ { 2 }$ -GP1 IgG autoantibodies specific for $\beta _ { 2 } { \mathrm { - G P 1 } }$ IgM autoantibodies specific for $\beta _ { 2 }$ -GP1 $\mathrm { I g A / I g G / I g M }$ autoantibodies specific for $\beta _ { 2 }$ -GP1   
D. Type of Test: Immunoassay, semi-quantitative or qualitative   
E. Applicant: IMMCO Diagnostics, Inc.

# F. Proprietary and Established Names:

ImmuLisa Enhanced™ B2GP1 IgA Antibody ELISA ImmuLisa Enhanced™ B2GP1 IgG Antibody ELISA ImmuLisa Enhanced™ B2GP1 IgM Antibody ELISA ImmuLisa Enhanced™ B2GP1 IgA/IgG/IgM Antibody ELISA

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S 8 6 6 . 5 6 6 0$ , Multiple Autoantibodies Immunological Test System

2. Classification: Class II

3. Product code: MSV, System, Test, Antibodies, β2-Glycoprotein I (β2-GPI)

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended uses:

ImmuLisa Enhanced™ B2GP1 IgA Antibody ELISA: Enzyme-linked immunosorbent assay (ELISA) for the qualitative or semi-quantitative detection of $\beta 2$ -GPI IgA antibodies in human serum to aid in diagnosis of autoimmune thrombotic disorders associated with antiphospholipid syndrome (APS) and APS with systemic lupus erythematosus (SLE) in conjunction with other laboratory tests and clinical findings.

ImmuLisa Enhanced™ B2GP1 IgG Antibody ELISA: Enzyme-linked immunosorbent assay (ELISA) for the qualitative or semi-quantitative detection of $\beta 2$ -GPI IgG antibodies in human serum to aid in diagnosis of autoimmune thrombotic disorders associated with antiphospholipid syndrome (APS) and APS with systemic lupus erythematosus (SLE) in conjunction with other laboratory tests and clinical findings.

ImmuLisa Enhanced™ B2GP1 IgM Antibody ELISA: Enzyme-linked immunosorbent assay (ELISA) for the qualitative or semi-quantitative detection of $\beta 2$ -GPI IgM antibodies in human serum to aid in diagnosis of autoimmune thrombotic disorders associated with antiphospholipid syndrome (APS) and APS with systemic lupus erythematosus (SLE) in conjunction with other laboratory tests and clinical findings.

ImmuLisa Enhanced™ B2GP1 IgA/IgG/IGM Antibody ELISA: Enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of $\beta 2$ -GPI IgA, IgG and IgM antibodies in human serum to aid in diagnosis of autoimmune thrombotic disorders associated with antiphospholipid syndrome (APS) and APS with systemic lupus erythematosus (SLE) in conjunction with other laboratory tests and clinical findings.

2. Indication for use: Same as intended use

3. Special conditions for use statement: For prescription use only

4. Special instrument requirements:

An ELISA microplate reader capable of reading absorbance values at $4 5 0 \mathrm { n m }$ . If a dual wavelength microplate reader is available, the reference filter should be set at 450/630 nm. An automatic microplate washer capable of accurately dispensing $2 0 0 \mu \mathrm { L }$ of fluid is also required.

# I. Device Description:

For ImmuLisa Enhanced™ B2GP1 IgA, or ImmuLisa Enhanced™ B2GP1 IgG, or ImmuLisa Enhanced™ B2GP1 IgM Antibody ELISA:

Each kit consists of 12 x 8 β2-GPI antigen coated microplate with individual break-away microwells; one negative control; three positive controls (one positive for β2-GPI IgA antibodies, one positive for $\beta 2$ -GPI IgG antibodies, and one positive for $\beta 2$ -GPI IgM antibodies); one set of five-level calibrators; three Horse radish peroxidase (HRP) conjugates (HRP goat anti-human IgA conjugate, HRP goat antihuman IgG conjugate and HRP goat anti-human IgM conjugate); TMB enzyme substrate; stop solution; and wash buffer. The results are read by a spectrophotometer at $4 5 0 \mathrm { n m }$ . Results are expressed in ELISA units per milliliter $\mathrm { ( E U / m L ) }$ . Semi-quantitative results are reported as: Negative $( < 2 0 ~ \mathrm { E U / m L } )$ ), Borderline/ Indeterminate $( 2 0 { - } 2 5 \mathrm { E U / m L } )$ and Positive $( > 2 5 \mathrm { \ E U / m L } )$ .

ImmuLisa Enhanced™ B2GP1 IgA/IgG/IgM Antibody ELISA:

Each kit consists of $1 2 \times 8$ β2-GPI antigen coated microplate with individual break-away microwells; negative control; positive control for $\beta 2$ -GPI antibodies; one-level calibrator; Horse radish peroxidase (HRP) goat anti-human $\mathrm { I g A / I g G / I g M }$ conjugate; TMB enzyme substrate; stop solution; wash buffer; and diluent. The results are read by a spectrophotometer at $4 5 0 \mathrm { n m }$ . Results are expressed in ELISA units per milliliter $\mathrm { ( E U / m L }$ ). Qualitative results are reported as Negative $( < 2 0 ~ \mathrm { E U / m L } )$ ) and Positive $( \ge 2 0$ $\mathrm { E U / m L }$ ).

# J. Substantial Equivalence Information:

1. Predicate device name(s) and 510(k) number(s):

Inova Quanta Lite® $\beta _ { 2 } \mathrm { G P 1 }$ IgA ELISA, K973006   
Inova Quanta Lite® $\beta _ { 2 } \mathrm { G P 1 }$ IgG ELISA, K970551   
Inova Quanta Lite® $\beta _ { 2 } \mathrm { G P 1 }$ IgM ELISA, K973014

# 2. Comparison with predicate:

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New DeviceImmuLisa EnhancedTM B2GP1IgA Antibody ELISA</td><td colspan="1" rowspan="1">PredicateQuanta Lite® β GP1IgA ELISA</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Enzyme-linked immunosorbent assay(ELISA) for the qualitative or semi-quantitative detection of β2-GPI IgAantibodies in human serum to aid indiagnosis of autoimmune thrombotic</td><td colspan="1" rowspan="1">Enzyme-linked immunosorbentassay (ELISA) for the semi-quantitative detection of β2-GPI IgAantibodies in human serum. Thepresence of β2-GPI IgA antibodies</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">disorders associated withantiphospholipid syndrome (APS) andAPS with systemic lupuserythematosus (SLE) in conjunctionwith other laboratory tests and clinicalfindings.</td><td colspan="1" rowspan="1">can be used in conjunction withclinical findings and other laboratorytests to aid in the diagnosis ofcertain autoimmune diseasethrombotic disorders, such as thosesecondary to systemic lupuserythematosus (SLE) or other lupus-like thrombotic diseases.</td></tr><tr><td colspan="1" rowspan="1">Assay Type</td><td colspan="1" rowspan="1">Manual ELISA</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Solid Phase</td><td colspan="1" rowspan="1">Polystyrene microplate wells</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Capture Antigen</td><td colspan="1" rowspan="1">Purified human β2-GPI</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Kit component set</td><td colspan="1" rowspan="1">Includes positive control, negativecontrol, calibrators, conjugate,substrate, diluent, wash buffer, stopsolution, microplate well</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Labeled DetectionAntibody (Conjugate)</td><td colspan="1" rowspan="1">Goat anti-human IgA conjugated tohorseradish peroxidase (HRP)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Substrate/ Chromogen</td><td colspan="1" rowspan="1">Tetramethylbenzidene (TMB)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Stop Solution</td><td colspan="1" rowspan="1">Sulfuric Acid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Dilution</td><td colspan="1" rowspan="1">1:101</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Incubation Times</td><td colspan="1" rowspan="1">Positive and negative controls, dilutedpatient samples: 30 minutesConjugate: 30 minutesSubstrate: 30 minutes (in the dark)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reaction Temperature</td><td colspan="1" rowspan="1">Room temperature (2025°C)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">International Reference Preparation isnot available. Results are traceable toin-house standards.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Positive Control</td><td colspan="1" rowspan="1">β2-GPI IgA antibodies</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Signal</td><td colspan="1" rowspan="1">Optical density</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">Microwell plate reader (450 nm)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">2-8°</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New DeviceImmuLisa EnhancedTM B2GP1IgA Antibody ELISA</td><td colspan="1" rowspan="1">PredicateQuanta Lite® β2 GP1RIgA ELISA</td></tr><tr><td colspan="1" rowspan="1">Assay Format</td><td colspan="1" rowspan="1">Semi-quantitative and qualitative</td><td colspan="1" rowspan="1">Semi-quantitative</td></tr><tr><td colspan="1" rowspan="1">Reported Unit</td><td colspan="1" rowspan="1">EU/mL</td><td colspan="1" rowspan="1">Standard IgA anti-β2-GPI unit(SAU)</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">Set of 5: Values in EU/mL: 160, 80 40,20, 1</td><td colspan="1" rowspan="1">Set of 5: Values in SAU: 150,75, 37.5 18.75 and 9.375</td></tr><tr><td colspan="1" rowspan="1">Wash Buffer</td><td colspan="1" rowspan="1">Powdered or optional liquidconcentrate</td><td colspan="1" rowspan="1">Liquid concentrate</td></tr><tr><td colspan="1" rowspan="1">Linear Range</td><td colspan="1" rowspan="1">3.6160 EU/mL</td><td colspan="1" rowspan="1">Not specified</td></tr><tr><td colspan="1" rowspan="1">Limit of Detection</td><td colspan="1" rowspan="1">3.6 EU/mL</td><td colspan="1" rowspan="1">Not specified</td></tr><tr><td colspan="1" rowspan="1">ResultsInterpretation</td><td colspan="1" rowspan="1">Negative: &lt; 20 EU/mLBorderline: 20-25 EU/mLPositive: &gt; 25 UE/mL</td><td colspan="1" rowspan="1">Negative: ≤ 20 SAUPositive: &gt; 20 SAU</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New DeviceImmuLisa EnhancedTM B2GPIIgG Antibody ELISA</td><td colspan="1" rowspan="1">PredicateQuanta Lite® β2 GPIRIgG ELISA</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Enzyme-linked immunosorbent assay(ELISA) for the qualitative or semi-quantitative detection of β2-GPI IgGantibodies in human serum to aid indiagnosis of autoimmune thromboticdisorders associated withantiphospholipid syndrome (APS) andAPS with systemic lupuserythematosus (SLE) in conjunctionwith other laboratory tests and clinicalfindings.</td><td colspan="1" rowspan="1">Enzyme-linked immunosorbentassay (ELISA) for the semi-quantitative detection of β2GPI IgG antibodies in humanserum. The presence of β2-GPIIgG antibodies can be used inconjunction with clinicalfindings and other laboratorytests to aid in the diagnosis ofcertain autoimmune diseasethrombotic disorders, such asthose secondary to systemiclupus erythematosus (SLE) orother lupus-like thromboticdiseases.</td></tr><tr><td colspan="1" rowspan="1">Assay Type</td><td colspan="1" rowspan="1">Manual ELISA</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Solid Phase</td><td colspan="1" rowspan="1">Polystyrene microplate wells</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Capture Antigen</td><td colspan="1" rowspan="1">Purified human β2-GPI</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Kit Component Set</td><td colspan="1" rowspan="1">Includes positive control, negativecontrol, calibrators, conjugate,substrate, diluent, wash buffer, stopsolution, microplate well.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Labeled DetectionAntibody (Conjugate)</td><td colspan="1" rowspan="1">Goat anti-human IgG conjugated toHRP</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Substrate/Chromogen</td><td colspan="1" rowspan="1">TMB</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Stop Solution</td><td colspan="1" rowspan="1">Sulfuric Acid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Dilution</td><td colspan="1" rowspan="1">1:101</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Incubation Times</td><td colspan="1" rowspan="1">Positive and negative controls, dilutedpatient samples: 30 minutesConjugate: 30 minutesSubstrate: 30 minutes (in the dark)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reaction Temperature</td><td colspan="1" rowspan="1">Room temperature (2025°C)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">International Reference Preparation isnot available. Results are traceable to</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">in-house standards.</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Positive Control</td><td colspan="1" rowspan="1">β2-GPI IgG antibodies</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">Microwell plate reader (450 nm)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">2-8°C</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New DeviceImmuLisa EnhancedTM B2GPIIgG Antibody ELISA</td><td rowspan=1 colspan=1>PredicateQuanta Lite β2 GPIIgG ELISA</td></tr><tr><td rowspan=1 colspan=1>Assay Format</td><td rowspan=1 colspan=1>Semi-quantitative and qualitative</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reported Unit</td><td rowspan=1 colspan=1>EU/mL</td><td rowspan=1 colspan=1>Standard IgG anti-β2-GPI unit(SGU)</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Set of 5: Values in EU/mL: 160, 80 40,20, 1</td><td rowspan=1 colspan=1>Set of 5: Values in SGU: 150,75, 37.5 18.75 and 9.375</td></tr><tr><td rowspan=1 colspan=1>Wash Buffer</td><td rowspan=1 colspan=1>Powdered or optional liquidconcentrate</td><td rowspan=1 colspan=1>Liquid concentrate</td></tr><tr><td rowspan=1 colspan=1>Linear Range</td><td rowspan=1 colspan=1>3.1-160 EU/mL</td><td rowspan=1 colspan=1>Not specified</td></tr><tr><td rowspan=1 colspan=1>Limit of Detection</td><td rowspan=1 colspan=1>3.1 EU/mL</td><td rowspan=1 colspan=1>Not specified</td></tr><tr><td rowspan=1 colspan=1>ResultsInterpretation</td><td rowspan=1 colspan=1>Negative: &lt; 20 EU/mLBorderline: 2025 EU/mLPositive: &gt; 25 EU/mL</td><td rowspan=1 colspan=1>Negative: ≤ 20 SGUPositive: &gt; 20 SGU</td></tr></table>

<table><tr><td colspan="3" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New DeviceImmuLisa EnhancedTM B2GPIIgM Antibody ELISA</td><td colspan="1" rowspan="1">PredicateQuanta Lite® β2 GPIIgM ELISA</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Enzyme-linked immunosorbent assay(ELISA) for the qualitative or semi-quantitative detection of β2-GPI IgMantibodies in human serum to aid indiagnosis of autoimmune thromboticdisorders associated withantiphospholipid syndrome (APS) andAPS with systemic lupuserythematosus (SLE) in conjunctionwith other laboratory tests and clinicalfindings.</td><td colspan="1" rowspan="1">Enzyme-linked immunosorbentassay (ELISA) for the semi-quantitative detection of β2-GPIIgM antibodies in humanserum. The presence of β2-GPIIgM antibodies can be used inconjunction with clinicalfindings and other laboratorytests to aid in the diagnosis ofcertain autoimmune diseasethrombotic disorders, such asthose secondary to systemiclupus erythematosus (SLE) orother lupus-like thromboticdiseases.</td></tr><tr><td colspan="1" rowspan="1">Assay Type</td><td colspan="1" rowspan="1">Manual ELISA</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Solid Phase</td><td colspan="1" rowspan="1">Polystyrene microplate wells</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Capture Antigen</td><td colspan="1" rowspan="1">Purified human β2-GPI</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Kit Component Set</td><td colspan="1" rowspan="1">Includes positive control, negativecontrol, calibrators, conjugate,substrate, diluent, wash buffer, stopsolution, microplate well.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Labeled DetectionAntibody Conjugate</td><td colspan="1" rowspan="1">Goat anti-human IgM conjugated toHRP</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Substrate/Chromogen</td><td colspan="1" rowspan="1">TMB</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Stop Solution</td><td colspan="1" rowspan="1">Sulfuric Acid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Dilution</td><td colspan="1" rowspan="1">1:101</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Incubation Times</td><td colspan="1" rowspan="1">Positive and negative controls dilutedpatient samples: 30 min.Conjugate: 30 minutes.Substrate: 30 minutes (in the dark).</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reaction Temperature</td><td colspan="1" rowspan="1">Room temperature (2025°C)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">International Reference Preparation isnot available. Results are traceable toin-house standards.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Positive Control</td><td colspan="1" rowspan="1">β2-GPI IgM antibodies</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">Microwell plate reader (450 nm)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">2-8°C</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New DeviceImmuLisa EnhancedTM B2GPIIgM Antibody ELISA</td><td rowspan=1 colspan=1>PredicateQuanta Lite® β2 GPI®IgM ELISA</td></tr><tr><td rowspan=1 colspan=1>Assay Format</td><td rowspan=1 colspan=1>Semi-quantitative and qualitative</td><td rowspan=1 colspan=1>Semi-quantitative</td></tr><tr><td rowspan=1 colspan=1>Reported Unit</td><td rowspan=1 colspan=1>EU/mL</td><td rowspan=1 colspan=1>Standard IgM anti-β2-GPI unit(SMU)</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Set of 5: Values in EU/mL: 160, 80 40,20, 1</td><td rowspan=1 colspan=1>Set of 5: Values in SMU: 150,75, 37.5 18.75 and 9.375</td></tr><tr><td rowspan=1 colspan=1>Wash Buffer</td><td rowspan=1 colspan=1>Powdered or optional liquidconcentrate</td><td rowspan=1 colspan=1>Liquid concentrate</td></tr><tr><td rowspan=1 colspan=1>Linear Range</td><td rowspan=1 colspan=1>2.3160 EU/mL</td><td rowspan=1 colspan=1>Not specified</td></tr><tr><td rowspan=1 colspan=1>Limit of Detection</td><td rowspan=1 colspan=1>2.3 EU/mL</td><td rowspan=1 colspan=1>Not specified</td></tr><tr><td rowspan=1 colspan=1>ResultsInterpretation</td><td rowspan=1 colspan=1>Negative: &lt; 20 EU/mLBorderline: 20-25 EU/mLPositive: &gt; 25 EU/mL</td><td rowspan=1 colspan=1>Negative: ≤ 20 SMUPositive: &gt; 20 SMU</td></tr></table>

<table><tr><td colspan="3">Similarities</td></tr><tr><td rowspan="3">Item</td><td>New Device</td><td>Predicates ®</td></tr><tr><td>ImmuLisa EnhancedTM B2GPI</td><td>Quanta Lite β2 GPI IgA ELISA ®</td></tr><tr><td>IgA/IgG/IgM Antibody ELISA</td><td>Quanta Lite β2 GPI IgG ELISA R Quanta Lite β2 GPI IgM ELISA</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Enzyme-linked immunosorbent assay(ELISA) for the qualitative or semi-quantitative detection of β2-GPIIgA/IgG/IgM antibodies in humanserum to aid in diagnosis ofautoimmune thrombotic disordersassociated with antiphospholipidsyndrome (APS) and APS withsystemic lupus erythematosus (SLE)in conjunction with other laboratorytests and clinical findings.</td><td colspan="1" rowspan="1">Enzyme-linked immunosorbentassay (ELISA) for the semi-quantitative detection of β2-GPIIgA, IgG or IgM antibodies inhuman serum. The presence ofβ2-GPI IgA, IgG or IgMantibodies can be used inconjunction with clinical findingsand other laboratory tests to aidin the diagnosis of certainautoimmune disease thromboticdisorders, such as thosesecondary to systemic lupuserythematosus (SLE) or otherlupus-like thrombotic diseases.</td></tr><tr><td colspan="1" rowspan="1">Assay Type</td><td colspan="1" rowspan="1">Manual ELISA</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Solid Phase</td><td colspan="1" rowspan="1">Polystyrene microplate wells</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Capture Antigen</td><td colspan="1" rowspan="1">Purified human β2-GPI</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Kit Component Set</td><td colspan="1" rowspan="1">Includes positive control, negativecontrol, calibrators, conjugate,substrate, diluent, wash buffer, stopsolution, microplate well.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Labeled DetectionAntibody(Conjugate)</td><td colspan="1" rowspan="1">Goat anti-human IgA conjugated toHRP, Goat anti-human IgGconjugated to HRP and Goat anti-human IgM conjugated to HRP</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Substrate/Chromogen</td><td colspan="1" rowspan="1">TMB</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Stop Solution</td><td colspan="1" rowspan="1">Sulfuric Acid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample Dilution</td><td colspan="1" rowspan="1">1:101</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Incubation Times</td><td colspan="1" rowspan="1">Positive and negative controls dilutedpatient samples: 30 minutesConjugate: 30 minutesSubstrate: 30 minutes (in the dark).</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reaction Temperature</td><td colspan="1" rowspan="1">Room temperature (2025°C)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability</td><td colspan="1" rowspan="1">International Reference Preparation isnot available. Results are traceable toin-house standards.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Positive Control</td><td colspan="1" rowspan="1">β2-GPI IgA/IgG/IgM antibodies</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">Microwell plate reader (450 nm)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Storage</td><td colspan="1" rowspan="1">2-8°C</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">New DeviceImmuLisa EnhancedTM B2GPIIgA/IgG/IgM Antibody ELISA</td><td colspan="1" rowspan="1">Predicateβ2GPI IgA ELISAβ2GPI IgG ELISAβ2GPI IgM ELISA</td></tr><tr><td colspan="1" rowspan="1">Assay Format</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Semi-quantitative</td></tr><tr><td colspan="1" rowspan="1">Reported Unit</td><td colspan="1" rowspan="1">EU/mL</td><td colspan="1" rowspan="1">SAU, SGU and SMU</td></tr><tr><td colspan="1" rowspan="1">Calibrators</td><td colspan="1" rowspan="1">30 EU/mL (one-point calibration)</td><td colspan="1" rowspan="1">Set of 5: Values in SAU, SGU orSMU: 150, 75, 37.5 18.75 and 9.375</td></tr><tr><td colspan="1" rowspan="1">Wash Buffer</td><td colspan="1" rowspan="1">Powdered or optional liquidconcentrate</td><td colspan="1" rowspan="1">Liquid Concentrate</td></tr><tr><td colspan="1" rowspan="1">Limit of Detection</td><td colspan="1" rowspan="1">2.7 EU/mL</td><td colspan="1" rowspan="1">Not specified</td></tr><tr><td colspan="1" rowspan="1">ResultsInterpretation</td><td colspan="1" rowspan="1">Negative: &lt; 20 EU/mLPositive: ≥ 20 EU/ mL</td><td colspan="1" rowspan="1">Negative: ≤ 20 SAU,SGU or SMUPositive:&gt; 20 SAU,SGU or SMU</td></tr></table>

# K. Standard/Guidance Document Referenced:

CLSI guideline EP05-A2, “Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline.”

CLSI guideline EP06-A, “Evaluation of the Linearity of Quantitative Analytical Measurement Procedures: A Statistical Approach.”

CLSI guideline EP07-A2, “Interference Testing in Clinical Chemistry; Approved Guideline – Second Edition.”

CLSI guideline EP09-A2, “Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline.”

CLSI guideline EP12-A2, “User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline – Second Edition.”

CLSI guideline EP17-A, “Protocols for Determination of Limits of Detection and Limits of Quantitation; Approved Guideline.”

# L. Test Principle:

The test is performed as a solid phase immunoassay. Controls, calibrators and patient sera are incubated in the $\beta 2$ -GPI antigen coated wells to allow specific antibodies present in the serum to bind to the antigen. Unbound antibodies and other serum proteins are removed by washing the microplate wells. Bound antibodies are detected by adding an enzyme-labeled anti-human IgA, IgG or IgM conjugate or combined anti-human $\mathrm { I g A / I g G / I g M }$ conjugate to the microplate wells. Unbound conjugate is removed by washing. Enzyme substrate (TMB) is then added to the wells and the presence of antibodies is

detected by a color change produced by the conversion of TMB substrate to a colored reaction product. The reaction is stopped and the intensity of the color change, which is proportional to the concentration of antibody, is read by a spectrophotometer at $4 5 0 \mathrm { n m }$ . Results are expressed in ELISA units per milliliter $\mathrm { \Delta E U / m L }$ ) and reported as positive or negative.

Semi-quantitative results are determined from a series of five calibrators ( $1 6 0 ~ \mathrm { E U / m L }$ , $8 0 ~ \mathrm { E U / m L }$ , 40 $\mathrm { E U / m L }$ , $2 0 \ : \mathrm { E U / m L }$ , and $1 \ : \mathrm { E U / m L }$ ). Values less than $2 0 \ : \mathrm { E U / m L }$ are considered negative results while values greater than $2 5 \mathrm { E U / m L }$ are considered positive; results between $2 0 \ : \mathrm { E U / m L }$ and $2 5 \mathrm { E U / m L }$ are considered ‘indeterminate’. The sponsor states the following recommendations in the Package Insert: “Indeterminate results should be retested and evaluated along with other laboratory methods; and when negative result occurs in the presence of clinical indications or when indeterminate results are obtained, lupus anti-coagulant and anti-cardiolipin antibody testing is recommended as additional testing.”

Qualitative results are determined using a ratio of the absorbance of the sample to the absorbance of the cut-off calibrator $( 2 0 \mathrm { E U / m L } )$ . The ratio is multiplied by the concentration of the cut-off calibrator to give a numerical value. Values greater than or equal to $2 0 \ : \mathrm { E U / m L }$ are considered positive and $< 2 0$ $\mathrm { E U / m L }$ values are considered negative.

# M. Performance Characteristics:

1. Analytical performance:

The results of all studies met the manufacturer’s pre-determined acceptance criteria.

a. Precision/Reproducibility:

Semi-Quantitative Precision:

Precision performance was evaluated in accordance with CLSI guideline EP05-A2. Native sera from the Intended Use population that cover the analytical measuring range were tested and included samples in the negative range, ${ \sim } 2 0 \%$ below cut-off, around the cut-off, ${ \sim } 2 0 \%$ above cut-off and in the moderate positive range of the assays. All specimens were assayed 12 times on one day to determine intra-assay repeatability. The same five specimens were also assayed across 13 runs with six repetitions in each over a period of four weeks to assess reproducibility at three sites using two sets of equipment. An additional 12 replicates were run on the first set of equipment (total replicates $= 9 0$ ). Assays were performed by two operators using one reagent lot and different equipment sets. The first operator performed the assay manually with a multi-channel pipettor, microplate washer and microplate reader. The second operator used an automatic system with a liquid handling system including a microplate reader. One assay lot was used for the study. Tabulated below are the precision and reproducibility results:

B2GPI IgA Semi-Quantitative Precision:   

<table><tr><td colspan="1" rowspan="2">Specimen</td><td colspan="1" rowspan="2">Mean(EU/mL)</td><td colspan="2" rowspan="1">Repeatability</td><td colspan="2" rowspan="1">Between Days</td><td colspan="2" rowspan="1">Total Imprecision</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV%</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV%</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV%</td></tr><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">9.1</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">8.1</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">10.8</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">13.6</td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">15.7</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">8.6</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">8.7</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">12.2</td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">20.9</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">8.7</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">10.2</td><td colspan="1" rowspan="1">2.8</td><td colspan="1" rowspan="1">13.5</td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">24.2</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">6.2</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">5.9</td><td colspan="1" rowspan="1">2.0</td><td colspan="1" rowspan="1">8.3</td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">54.0</td><td colspan="1" rowspan="1">1.4</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">2.4</td><td colspan="1" rowspan="1">4.4</td><td colspan="1" rowspan="1">2.7</td><td colspan="1" rowspan="1">5.1</td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">106.7</td><td colspan="1" rowspan="1">4.2</td><td colspan="1" rowspan="1">4.2</td><td colspan="1" rowspan="1">4.6</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">5.9</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">153.1</td><td colspan="1" rowspan="1">9.2</td><td colspan="1" rowspan="1">6.5</td><td colspan="1" rowspan="1">9.0</td><td colspan="1" rowspan="1">5.8</td><td colspan="1" rowspan="1">12.9</td><td colspan="1" rowspan="1">8.4</td></tr></table>

B2GPI IgG Semi-Quantitative Precision:   

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=2>TotalImprecisionManual/Operator #1</td><td rowspan=1 colspan=2>TotalImprecisionAutomated/Operator # 2</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>11.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>15.7</td><td rowspan=1 colspan=1>1.32</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>1.39</td><td rowspan=1 colspan=1>8.8</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>20.9</td><td rowspan=1 colspan=1>1.88</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>2.17</td><td rowspan=1 colspan=1>10.4</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>24.2</td><td rowspan=1 colspan=1>1.66</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>54.0</td><td rowspan=1 colspan=1>2.19</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>2.27</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>106.7</td><td rowspan=1 colspan=1>4.15</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>5.52</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>153.1</td><td rowspan=1 colspan=1>8.34</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>10.1</td><td rowspan=1 colspan=1>6.6</td></tr></table>

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between Days</td><td rowspan=1 colspan=2>TotalImprecision</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10.1</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>14.6</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>15.6</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>5.4</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>21.2</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>25.0</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>56.0</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>6.2</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>109.8</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>5.3</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>154.0</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>5.5</td></tr></table>

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=2>TotalImprecisionManual/Operator #1</td><td rowspan=1 colspan=2>TotalImprecisionAutomated/Operator # 2</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10.1</td><td rowspan=1 colspan=1>1.01</td><td rowspan=1 colspan=1>10.0</td><td rowspan=1 colspan=1>1.22</td><td rowspan=1 colspan=1>12.1</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>15.6</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>0.70</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>21.2</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>1.23</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>25.0</td><td rowspan=1 colspan=1>1.24</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>1.09</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>56.0</td><td rowspan=1 colspan=1>2.69</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>3.41</td><td rowspan=1 colspan=1>6.1</td></tr></table>

B2GPI IgM Semi-Quantitative Precision:   

<table><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>109.8</td><td rowspan=1 colspan=1>6.04</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>5.63</td><td rowspan=1 colspan=1>5.1</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>154.0</td><td rowspan=1 colspan=1>9.06</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>7.47</td><td rowspan=1 colspan=1>4.9</td></tr></table>

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=2>Repeatability</td><td rowspan=1 colspan=2>Between Days</td><td rowspan=1 colspan=2>TotalImprecision</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>8.9</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>15.0</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>17.3</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>11.5</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>19.7</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>10.6</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>26.1</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>6.1</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>83.7</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>114.8</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>8.0</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>159.4</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>9.4</td><td rowspan=1 colspan=1>5.9</td></tr></table>

<table><tr><td rowspan=2 colspan=1>Specimen</td><td rowspan=2 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=2>TotalImprecisionManual/Operator #1</td><td rowspan=1 colspan=2>TotalImprecisionAutomated/Operator # 2</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>11.1</td><td rowspan=1 colspan=1>0.98</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>1.35</td><td rowspan=1 colspan=1>12.2</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>17.3</td><td rowspan=1 colspan=1>1.93</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>1.36</td><td rowspan=1 colspan=1>7.9</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>19.7</td><td rowspan=1 colspan=1>1.88</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>2.18</td><td rowspan=1 colspan=1>11.1</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>26.1</td><td rowspan=1 colspan=1>1.20</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>1.60</td><td rowspan=1 colspan=1>6.1</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>83.7</td><td rowspan=1 colspan=1>3.74</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>4.07</td><td rowspan=1 colspan=1>4.9</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>114.8</td><td rowspan=1 colspan=1>8.51</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>9.51</td><td rowspan=1 colspan=1>8.3</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>159.4</td><td rowspan=1 colspan=1>6.42</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>9.00</td><td rowspan=1 colspan=1>5.6</td></tr></table>

# Qualitative Reproducibility:

Studies were performed under the guidance of CLSI EP12-A2. Ninety replicates each of native sera in the negative range, ${ \sim } 2 0 \%$ below cut-off, at \~cut-off, ${ \sim } 2 0 \%$ above cut-off and in the moderate positive range of the assays were tested for qualitative reproducibility. These samples were tested in multiple runs same as in semi-quantitative precision study. The results of these studies are presented in the tables below.

# Qualitative Reproducibility:

B2GPI IgA Qualitative Precision:   

<table><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=1>% Negative</td><td rowspan=1 colspan=1>% Positive</td></tr><tr><td rowspan=1 colspan=1>Low Negative</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Cut-off -20%</td><td rowspan=1 colspan=1>15.4</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr></table>

B2GPI IgG Qualitative Precision:   

<table><tr><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>20.9</td><td rowspan=1 colspan=1>23.3</td><td rowspan=1 colspan=1>76.7</td></tr><tr><td rowspan=1 colspan=1>Cut-off +20%</td><td rowspan=1 colspan=1>24.2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>64.8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Moderate to High Pos</td><td rowspan=1 colspan=1>128.6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr></table>

B2GPI IgM Qualitative Precision:   

<table><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=1>% Negative</td><td rowspan=1 colspan=1>% Positive</td></tr><tr><td rowspan=1 colspan=1>Low Negative</td><td rowspan=1 colspan=1>9.8</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Cut-off -20%</td><td rowspan=1 colspan=1>14.8</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>20.8</td><td rowspan=1 colspan=1>23.3</td><td rowspan=1 colspan=1>76.7</td></tr><tr><td rowspan=1 colspan=1>Cut-off +20%</td><td rowspan=1 colspan=1>24.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>59.4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Moderate to High Pos</td><td rowspan=1 colspan=1>96.7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr></table>

B2GPI $\mathrm { I g A / I g G / I g M }$ Qualitative Precision:   

<table><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=1>% Negative</td><td rowspan=1 colspan=1>% Positive</td></tr><tr><td rowspan=1 colspan=1>Low Negative</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Cut-off -20%</td><td rowspan=1 colspan=1>14.5</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>19.7</td><td rowspan=1 colspan=1>61.1</td><td rowspan=1 colspan=1>38.9</td></tr><tr><td rowspan=1 colspan=1>Cut-off +20%</td><td rowspan=1 colspan=1>26.1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>100.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Moderate to High Pos</td><td rowspan=1 colspan=1>151.4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=1>% Negative</td><td rowspan=1 colspan=1>% Positive</td></tr><tr><td rowspan=1 colspan=1>Low Negative</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Cut-off -20%</td><td rowspan=1 colspan=1>17.4</td><td rowspan=1 colspan=1>97.8</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>19.8</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>50</td></tr><tr><td rowspan=1 colspan=1>Cut-off +20%</td><td rowspan=1 colspan=1>24.8</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Moderate Positive</td><td rowspan=1 colspan=1>62.7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Moderate to High Pos</td><td rowspan=1 colspan=1>135.9</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr></table>

# Lot-to-Lot Reproducibility:

Lot-to-lot reproducibility was tested by using samples spanning the assay range, similar to the samples used in the precision study, above. Three assay lots were used in the study. Assays were performed by two operators using different equipment sets. The first operator performed the assay manually with a multichannel pipettor, microplate washer and microplate reader. The second

operator used an automatic system with a liquid handling system including a microplate reader. Each of the seven samples below was tested in three runs with three replicates over three days on each of the three assay lots (81 replicates/sample).

B2GPI IgA Lot-to-Lot Reproducibility:   

<table><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=1>Lot 1 CV%</td><td rowspan=1 colspan=1>Lot 2 CV%</td><td rowspan=1 colspan=1>Lot 3 CV%</td><td rowspan=1 colspan=1>Inter-Lot CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10.2</td><td rowspan=1 colspan=1>9.6</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>12.6</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>16.0</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>9.5</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>20.8</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>7.9</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>25.7</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>8.7</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>56.5</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>6.4</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>114.9</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>5.6</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>168.1</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>8.3</td></tr></table>

B2GPI IgG Lot-to-Lot Reproducibility:   

<table><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=1>Lot 1 CV%</td><td rowspan=1 colspan=1>Lot 2 CV%</td><td rowspan=1 colspan=1>Lot 3 CV%</td><td rowspan=1 colspan=1>Inter-Lot CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>12.6</td><td rowspan=1 colspan=1>7.5</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>6.3</td><td rowspan=1 colspan=1>9.0</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>15.7</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>6.6</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>21.3</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>8.4</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>26.3</td><td rowspan=1 colspan=1>7.2</td><td rowspan=1 colspan=1>7.4</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>8.4</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>52.8</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>5.3</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>110.7</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>6.6</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>158.3</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>5.1</td></tr></table>

B2GPI IgM Lot-to-Lot Reproducibility:   

<table><tr><td rowspan=8 colspan=1>B</td><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=1>Lot 1 CV%</td><td rowspan=1 colspan=1>Lot 2 CV%</td><td rowspan=1 colspan=1>Lot 3 CV%</td><td rowspan=1 colspan=1>Inter-Lot CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>13.0</td><td rowspan=1 colspan=1>13.8</td><td rowspan=1 colspan=1>13.7</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>15.3</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>9.5</td><td rowspan=1 colspan=1>10.1</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>20.7</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>7.1</td><td rowspan=1 colspan=1>6.8</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>27.2</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>6.3</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>85.3</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>6.0</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>112.7</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>9.2</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>160.6</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>6.3</td></tr></table>

B2GPI IgA/IgG/IgM Lot-to-Lot Reproducibility:   

<table><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Mean(EU/mL)</td><td rowspan=1 colspan=1>Lot 1 CV%</td><td rowspan=1 colspan=1>Lot 2 CV%</td><td rowspan=1 colspan=1>Lot 3 CV%</td><td rowspan=1 colspan=1>Inter-Lot CV%</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>9.7</td><td rowspan=1 colspan=1>12.1</td><td rowspan=1 colspan=1>11.3</td><td rowspan=1 colspan=1>12.4</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>16.7</td><td rowspan=1 colspan=1>7.7</td><td rowspan=1 colspan=1>5.8</td><td rowspan=1 colspan=1>8.1</td><td rowspan=1 colspan=1>7.5</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>18.7</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>7.7</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>24.7</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>7.2</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>63.4</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>9.1</td><td rowspan=1 colspan=1>8.0</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>132.8</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>6.7</td></tr></table>

# $b$ .Linearity/assay reportable range:

Linearity and recovery were tested by diluting positive specimens with equidistant dilutions across the measuring range and comparing actual vs. expected results. The linear range of the IgA assay was determined to be $3 . 6 { - } 1 6 0 \mathrm { E U } / \mathrm { m l } .$ . The linear range of the IgG assay was determined to be $3 . 1 \mathrm { - } 1 6 0 \mathrm { E U / m l } .$ . The linear range of the IgM assay was determined to be 2.3– $1 6 0 \mathrm { E U / m l }$ . Results of the linear regression analysis are summarized below:

B2GPI IgA:   

<table><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Dilution Range(EU/mL)</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Y-Intercept(95% CI)</td><td rowspan=1 colspan=1>$R^{2$</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2.3 to 17.8</td><td rowspan=1 colspan=1>1.06(0.89 to 1.21)</td><td rowspan=1 colspan=1>-0.59(-2.4 to 1.2)</td><td rowspan=1 colspan=1>0.9767</td><td rowspan=1 colspan=1>88% to 112%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>11.0 to 63.9</td><td rowspan=1 colspan=1>1.05(0.97 to 1.14)</td><td rowspan=1 colspan=1>-0.77(-4.2 to 2.6)</td><td rowspan=1 colspan=1>0.9934</td><td rowspan=1 colspan=1>93% to105%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>59.0 to 168.3</td><td rowspan=1 colspan=1>1.08(0.94 to 1.22)</td><td rowspan=1 colspan=1>-0.68(-16.7 to 15.4)</td><td rowspan=1 colspan=1>0.9915</td><td rowspan=1 colspan=1>90% to 100%</td></tr></table>

B2GPI IgG:   

<table><tr><td rowspan=3 colspan=1>B</td><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Dilution Range(EU/mL)</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Y-Intercept(95% CI)</td><td rowspan=1 colspan=1>$R^{2</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2.1 to 41.4</td><td rowspan=1 colspan=1>1.04(0.89 to1.19)</td><td rowspan=1 colspan=1>0.2(-1.8 to 4.9)</td><td rowspan=1 colspan=1>0.9807</td><td rowspan=1 colspan=1>82% to 100%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>4.1 to 140.9</td><td rowspan=1 colspan=1>1.03(0.93 to 1.13)</td><td rowspan=1 colspan=1>4.13(-3.9 to 12.1)</td><td rowspan=1 colspan=1>0.9905</td><td rowspan=1 colspan=1>86% to100%</td></tr><tr><td rowspan=1 colspan=1>B</td><td rowspan=1 colspan=1>B2GP13gM:</td><td rowspan=1 colspan=1>3.3 to 198.1</td><td rowspan=1 colspan=1>0.99(0.91 to 1.07)</td><td rowspan=1 colspan=1>7.25(-1.8 to 16.3)</td><td rowspan=1 colspan=1>0.9936</td><td rowspan=1 colspan=1>82% to 100%</td></tr></table>

B2GPI IgM:   

<table><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Dilution Range(EU/mL)</td><td rowspan=1 colspan=1>Slope(95% CI)</td><td rowspan=1 colspan=1>Y-Intercept(95% CI)</td><td rowspan=1 colspan=1>$R^{2</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1.7 to 63.4</td><td rowspan=1 colspan=1>1.00(0.95 to 1.05)</td><td rowspan=1 colspan=1>1.8(-0.1 to 3.6)</td><td rowspan=1 colspan=1>0.9974</td><td rowspan=1 colspan=1>81% to100%</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>5.4 to 87.5</td><td rowspan=1 colspan=1>1.02(0.93 to 1.10)</td><td rowspan=1 colspan=1>2.3(-1.9 to 6.4)</td><td rowspan=1 colspan=1>0.9936</td><td rowspan=1 colspan=1>89% to100%</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>54.7 to 173.5</td><td rowspan=1 colspan=1>0.96(0.82 to 1.09)</td><td rowspan=1 colspan=1>3.1(-13.1 to 19.4)</td><td rowspan=1 colspan=1>0.9963</td><td rowspan=1 colspan=1>86% to 100%</td></tr></table>

High dose hook effect: High antibody concentrations specimens above $1 6 0 ~ \mathrm { E U / m L }$ were tested. No hook effect was demonstrated in dilution sample levels up to $2 2 8 . 6 \mathrm { E U / m L }$ for IgA; 597.6 $\mathrm { E U / m L }$ for IgG; and $6 0 5 . 5 \mathrm { E U / m L }$ for IgM.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

i. Traceability:

There are currently no recognized international standards for the measurement of $\beta 2$ -GP1 IgA, β2-GP1 IgG and β2-GP1 IgM antibodies. Calibrator and Control values are directly traceable to in-house standards.

# ii. Value Assignment:

Calibrators and Positive Controls are dilutions of pooled $\beta 2$ -GP1 IgA, β2-GP1 IgG or $\beta 2 \cdot$ - GP1 IgM antibody positive sera. IMMCO formulates new calibrator and control lots from an array of antibody positive sera obtained from various commercial plasma centers. The calibrators and controls are taken from different pooled sera. All source sera have been tested and found negative for infectious disease as stated in the product insert. Manufactured calibrator sets are stored in aliquots frozen at $- 7 0 \mathrm { { } ^ { \circ } C }$ . As new lots of calibrators are developed, comparison studies are performed to calibrate values against original calibrators.

iii. Stability:

Shelf life stability:

Accelerated and open kit stability studies for each device were performed on three lots of components/reagents. Accelerated studies were conducted with materials incubated at $3 7 ^ { \circ } \mathrm { C }$ . In these conditions, one day is considered equivalent to one month stored at $2 ^ { \circ } { - } 8 ^ { \circ } \mathrm { C }$ . Materials are removed from the incubator for testing at three-day intervals for a minimum of 21 days.

Data from accelerated stability study support an18-month shelf life stability claim. Real-time stability testing is on-going.

# Open Kit Stability:

For open kit stability studies, materials are opened and stored in a dark environment as required for bench-top usage, then assayed at 15, 45 and 90 day intervals. Open vial stability studies demonstrate opened reagents are stable at 45 days, but the sponsor chose a more restrictive one month open kit stability claim.

# d. Detection limit:

The Limit of Blank (LoB) and the Limit of Detection (LoD) were determined by following CLSI EP17-A. Sixty samples of diluent were run as blank samples for LoB and six different normal human sera for LoD were each assayed 10 times. The LoB was determined to be $2 . 6 \mathrm { E U } / \mathrm { m l }$ for β2-GP1 IgA, 2.3 EU/mL for β2-GP1 IgG, 1.4 EU/mL for β2-GP1 IgM and $1 . 9 \ : \mathrm { E U / m L }$ β2-GP1 $\mathrm { I g A / I g G / I g M }$ . The LoD was determined to be $3 . 6 ~ \mathrm { E U / m L }$ for β2-GP1 IgA, 3.1 EU/mL for $\beta 2 \cdot$ - GP1 IgG, 2.3 EU/mL for β2-GP1 IgM and 2.7 for $\beta 2$ -GP1 IgA/IgG/IgM.

# e. Analytical specificity:

# Endogenous Interference:

The studies were performed according to CLSI EP07-A2. Interference was studied by mixing sera with known β2-GP1 antibody levels with potentially interfering serum samples and studying deviation from expected results. Known levels of antibodies included negative, around the cut-off and low positive (i.e. 2–5 times the cut-off). No significant interference was demonstrated in for β2-GP1 IgA, $\beta 2$ -GP1 IgG, β2-GP1 IgM or β2-GP1 $\mathrm { I g A / I g G / I g M }$ with the following substances at the levels indicated: Hemoglobin $( 2 \ \mathrm { g / L } )$ , Bilirubin (342 $\mu \mathrm { m o l / L } )$ , Rheumatoid Factor $\mathrm { 1 0 0 \ I U / m L } )$ , Triglycerides $( 3 7 { \mathrm { m m o l } } / { \mathrm { L } } )$ ), Cholesterol (13 $\mathrm { m m o l / L } )$ , Heparin $\left( 3 0 0 0 \mathrm { U / L } \right)$ , Acetylsalicylic Acid $( 3 . 6 2 \mathrm { m m o l / L } )$ , Prednisone (0.84 $\mu \mathrm { m o l / L } )$ , Warfarin $( 3 2 . 5 \ \mu \mathrm { m o l / L } )$ ), Hydroxychloroquine $( 1 4 8 \mathrm { \ : \mu m o l / L } )$ , Rituximab (75 $\mu \mathrm { g } / \mathrm { m L } )$ and Atorvastatin $( 6 0 0 \mu \mathrm { g } \mathrm { E Q / L } )$ .

# Cross-reactivity:

Numerous potentially cross-reactive autoimmune and infectious disease sera were tested for B2GP1 antibodies for β2-GP1 IgA, β2-GP1 IgG, β2-GP1 IgM or β2-GP1 $\mathrm { I g A / I g G / I g M } .$ . Results for each assay are provided in the following table:

<table><tr><td colspan="1" rowspan="1"></td><td colspan="8" rowspan="1">ImmuLisa™M B2GP1 Antibody ELISAs</td></tr><tr><td colspan="1" rowspan="2">Condition</td><td colspan="2" rowspan="1">B2GP1 IgA</td><td colspan="2" rowspan="1">B2GP1 IgG</td><td colspan="2" rowspan="1">B2GP1 IgM</td><td colspan="2" rowspan="1">B2GP1IgA/IgG/IgM</td></tr><tr><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">% Pos</td><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">% Pos</td><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">% Pos</td><td colspan="1" rowspan="1">n</td><td colspan="1" rowspan="1">% Pos</td></tr><tr><td colspan="1" rowspan="1">Syphilis</td><td colspan="1" rowspan="1">7/40</td><td colspan="1" rowspan="1">17.5</td><td colspan="1" rowspan="1">3/40</td><td colspan="1" rowspan="1">7.5</td><td colspan="1" rowspan="1">5/40</td><td colspan="1" rowspan="1">12.5</td><td colspan="1" rowspan="1">8/37</td><td colspan="1" rowspan="1">21.6</td></tr><tr><td colspan="1" rowspan="1">HCV</td><td colspan="1" rowspan="1">0/32</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">2/32</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">1/32</td><td colspan="1" rowspan="1">3.1</td><td colspan="1" rowspan="1">2/32</td><td colspan="1" rowspan="1">6.3</td></tr><tr><td colspan="1" rowspan="1">Celiac</td><td colspan="1" rowspan="1">0/16</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/22</td><td colspan="1" rowspan="1">4.5</td></tr><tr><td colspan="1" rowspan="1">Polymyositis</td><td colspan="1" rowspan="1">3/17</td><td colspan="1" rowspan="1">17.6</td><td colspan="1" rowspan="1">0/17</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/17</td><td colspan="1" rowspan="1">5.9</td><td colspan="1" rowspan="1">2/17</td><td colspan="1" rowspan="1">11.8</td></tr><tr><td colspan="1" rowspan="1">Dermatomyositis</td><td colspan="1" rowspan="1">2/12</td><td colspan="1" rowspan="1">16.7</td><td colspan="1" rowspan="1">0/12</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/12</td><td colspan="1" rowspan="1">8.3</td><td colspan="1" rowspan="1">0/12</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">Rheumatoid Arthritis</td><td colspan="1" rowspan="1">6/46</td><td colspan="1" rowspan="1">13.0</td><td colspan="1" rowspan="1">4/60</td><td colspan="1" rowspan="1">6.7</td><td colspan="1" rowspan="1">0/60</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">3/45</td><td colspan="1" rowspan="1">6.7</td></tr><tr><td colspan="1" rowspan="1">Systemic Sclerosis</td><td colspan="1" rowspan="1">3/31</td><td colspan="1" rowspan="1">9.7</td><td colspan="1" rowspan="1">3/23</td><td colspan="1" rowspan="1">13.0</td><td colspan="1" rowspan="1">1/23</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">2/23</td><td colspan="1" rowspan="1">8.7</td></tr><tr><td colspan="1" rowspan="1">Sjögren's</td><td colspan="1" rowspan="1">2/37</td><td colspan="1" rowspan="1">5.4</td><td colspan="1" rowspan="1">5/37</td><td colspan="1" rowspan="1">13.5</td><td colspan="1" rowspan="1">2/37</td><td colspan="1" rowspan="1">5.4</td><td colspan="1" rowspan="1">2/37</td><td colspan="1" rowspan="1">5.4</td></tr><tr><td colspan="1" rowspan="1">Stroke</td><td colspan="1" rowspan="1">1/15</td><td colspan="1" rowspan="1">6.7</td><td colspan="1" rowspan="1">0/15</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/15</td><td colspan="1" rowspan="1">6.7</td><td colspan="1" rowspan="1">1/15</td><td colspan="1" rowspan="1">6.7</td></tr><tr><td colspan="1" rowspan="1">Epilepsy</td><td colspan="1" rowspan="1">1/14</td><td colspan="1" rowspan="1">7.1</td><td colspan="1" rowspan="1">0/14</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/14</td><td colspan="1" rowspan="1">7.1</td><td colspan="1" rowspan="1">1/14</td><td colspan="1" rowspan="1">7.1</td></tr><tr><td colspan="1" rowspan="1">Arterial Thrombosis</td><td colspan="1" rowspan="1">1/15</td><td colspan="1" rowspan="1">6.7</td><td colspan="1" rowspan="1">2/15</td><td colspan="1" rowspan="1">13.3</td><td colspan="1" rowspan="1">1/15</td><td colspan="1" rowspan="1">6.7</td><td colspan="1" rowspan="1">3/15</td><td colspan="1" rowspan="1">20.0</td></tr><tr><td colspan="1" rowspan="1">Venous Thrombosis</td><td colspan="1" rowspan="1">0/15</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/15</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/15</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/15</td><td colspan="1" rowspan="1">6.7</td></tr><tr><td colspan="1" rowspan="1">Myocardial Infarction</td><td colspan="1" rowspan="1">3/20</td><td colspan="1" rowspan="1">15.0</td><td colspan="1" rowspan="1">0/20</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/20</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">4/20</td><td colspan="1" rowspan="1">20.0</td></tr><tr><td colspan="1" rowspan="1">Acute Coronary Syndrome</td><td colspan="1" rowspan="1">1/10</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">0/10</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/10</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/10</td><td colspan="1" rowspan="1">10.0</td></tr><tr><td colspan="1" rowspan="1">Pre-eclampsia</td><td colspan="1" rowspan="1">0/20</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">3/20</td><td colspan="1" rowspan="1">15.0</td><td colspan="1" rowspan="1">0/20</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/20</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">SNHL</td><td colspan="1" rowspan="1">0/0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/10</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/0</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/7</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">Hashimoto's</td><td colspan="1" rowspan="1">0/7</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/20</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/20</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/7</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">Graves</td><td colspan="1" rowspan="1">3/25</td><td colspan="1" rowspan="1">12.0</td><td colspan="1" rowspan="1">1/18</td><td colspan="1" rowspan="1">5.6</td><td colspan="1" rowspan="1">0/18</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/20</td><td colspan="1" rowspan="1">5.0</td></tr><tr><td colspan="1" rowspan="1">Wegener's</td><td colspan="1" rowspan="1">4/45</td><td colspan="1" rowspan="1">8.9</td><td colspan="1" rowspan="1">0/34</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/34</td><td colspan="1" rowspan="1">2.9</td><td colspan="1" rowspan="1">1/42</td><td colspan="1" rowspan="1">2.4</td></tr><tr><td colspan="1" rowspan="1">Churg-Strauss</td><td colspan="1" rowspan="1">3/23</td><td colspan="1" rowspan="1">13.0</td><td colspan="1" rowspan="1">1/23</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">0/23</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">2/23</td><td colspan="1" rowspan="1">8.7</td></tr><tr><td colspan="1" rowspan="1">Crohn's</td><td colspan="1" rowspan="1">0/20</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/20</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">0/20</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/20</td><td colspan="1" rowspan="1">5.0</td></tr><tr><td colspan="1" rowspan="1">Ulcerative Colitis</td><td colspan="1" rowspan="1">1/20</td><td colspan="1" rowspan="1">5.0</td><td colspan="1" rowspan="1">2/20</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">2/20</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">2/20</td><td colspan="1" rowspan="1">10.0</td></tr><tr><td colspan="1" rowspan="1">Toxoplasma</td><td colspan="1" rowspan="1">0/10</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/10</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">1/10</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">1/10</td><td colspan="1" rowspan="1">10.0</td></tr><tr><td colspan="1" rowspan="1">CMV</td><td colspan="1" rowspan="1">0/10</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1/10</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">1/10</td><td colspan="1" rowspan="1">10.0</td><td colspan="1" rowspan="1">2/10</td><td colspan="1" rowspan="1">20.0</td></tr><tr><td colspan="1" rowspan="1">Rubella</td><td colspan="1" rowspan="1">0/10</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/10</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/10</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0/10</td><td colspan="1" rowspan="1">0.0</td></tr><tr><td colspan="1" rowspan="1">Total</td><td colspan="1" rowspan="1">41/623</td><td colspan="1" rowspan="1">6.5</td><td colspan="1" rowspan="1">29/534</td><td colspan="1" rowspan="1">5.4</td><td colspan="1" rowspan="1">20/515</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">41/581</td><td colspan="1" rowspan="1">7.0</td></tr></table>

The ‘Limitations of Procedure’ section of the Package Insert states: $^ { \circ } A$ diagnosis cannot be made on the basis of anti-B2GP1 results alone. The results of other laboratory tests supporting diagnosis of APS, SLE and associated thrombotic conditions in at-risk patients, particularly anticardiolipin antibody and lupus anticoagulant tests, must be considered along with clinical findings.”

f. Assay cut-off:

The cutoff was established by testing a population of 62 normal healthy subjects (NHS) for β2- GP1IgA, β2-GP1IgG, β2-GP1IgM and 60 NHS for $\mathrm { \beta 2 { - } G P 1 I g A / I g G / I g M ) }$ and calculating the mean of the normal subjects plus 2.5 SD for IgA, mean plus 3 SD for IgG, mean plus 2.5 for IgM and mean plus 2 for $\mathrm { I g A / I g G / I g M }$ as supported by receiver operatory curve (ROC) analysis. The cutoff was assigned an arbitrary value of 20 EU/mL.

β2-GP1 Interpretation <20 EU/mL Negative   
20 – 25 EU/mL Indeterminate (Borderline)\* >25 EU/mL Positive

\*The B2GP1 $\mathrm { I g A / I g G / I g M }$ ELISA is qualitative and values greater than or equal to 20 EU/mL are reported as positive.

2. Comparison studies:

a. Method comparison with predicate devices: ImmuLisa™ B2GP1 Antibody ELISAs were tested in comparison with analogous Quanta Lite kits using sera from patients with autoimmune diseases associated with β2-GP1 antibodies (disease-associated population: APS, SLE, APS with SLE), patients with a suspected diagnosis of APS and SLE submitted for reference laboratory testing and patients with infectious diseases and other autoimmune conditions (disease control population). The number of specimens tested for each ImmuLisa™ B2GP1 Antibody ELISA varies and is indicated in the respective tables.

Only specimens in the linear range of the assays were included in the method comparison. Greater than $1 5 \%$ of the test cases were the cutoff of the assay. Normal human sera were excluded from the method comparison.

The samples used in the method comparison study for the β2-GP1 IgA, β2-GP1 IgG, β2-GP1 $\mathrm { I g M }$ and β2-GP1 $\mathrm { I g A / I g G / I g M }$ are shown in the table below:

<table><tr><td colspan="1" rowspan="1">ImmuLisa™M B2GP1 AntibodyELISAs</td><td colspan="1" rowspan="1">B2GP1IgA</td><td colspan="1" rowspan="1">B2GP1 IgG</td><td colspan="1" rowspan="1">B2GP1 IgM</td><td colspan="1" rowspan="1">B2GP1IgA/IgG/IgM</td></tr><tr><td colspan="5" rowspan="1">Number and type of clinical samples tested on each ImmuLisa™M B2GP1 Antibody ELISA</td></tr><tr><td colspan="5" rowspan="1">Total Specimens                              n=328         n=338          n=355            n=331</td></tr><tr><td colspan="5" rowspan="1">Disease-associated population            n= 153       n=154            n=169          n=176</td></tr><tr><td colspan="1" rowspan="1">Antiphospholipid syndrome (APS)</td><td colspan="1" rowspan="1">91</td><td colspan="1" rowspan="1">82</td><td colspan="1" rowspan="1">96</td><td colspan="1" rowspan="1">87</td></tr><tr><td colspan="1" rowspan="1">Systemic lupus erythematosus (SLE)</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">21</td></tr><tr><td colspan="1" rowspan="1">APS with SLE</td><td colspan="1" rowspan="1">36</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">68</td></tr><tr><td colspan="5" rowspan="1">Suspected diagnosis                           n=50           n=52            n=52           n=48</td></tr><tr><td colspan="1" rowspan="1">Suspected diagnosis of APS</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">32</td><td colspan="1" rowspan="1">28</td></tr><tr><td colspan="1" rowspan="1">Suspected diagnosis of SLE</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="5" rowspan="1">Disease controls                               n=125         n=132           n=134           n=107</td></tr><tr><td colspan="5" rowspan="1">Autoimmune conditions                       n=70           n=75          n=81             n=56</td></tr><tr><td colspan="1" rowspan="1">Celiac</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Rheumatoid Arthritis</td><td colspan="1" rowspan="1">24</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">19</td></tr><tr><td colspan="1" rowspan="1">Systemic Sclerosis</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">6</td></tr><tr><td colspan="1" rowspan="1">Sjögren's</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">14</td></tr><tr><td colspan="1" rowspan="1">Wegener's granulomatosus</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">3</td></tr><tr><td colspan="1" rowspan="1">Churg-Strauss</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">1</td></tr><tr><td colspan="1" rowspan="1">Graves' Disease</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">13</td></tr><tr><td colspan="1" rowspan="1">Hashimoto's Disease</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">ImmuLisaTM B2GP1 AntibodyELISAs</td><td colspan="1" rowspan="1">B2GP1IgA</td><td colspan="1" rowspan="1">B2GP1 IgG</td><td colspan="1" rowspan="1">B2GP1 IgM</td><td colspan="1" rowspan="1">B2GP1IgA/IgG/IgM</td></tr><tr><td colspan="1" rowspan="1">Sensory Neuronal Hearing Loss</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="5" rowspan="1">Infectious diseases                           n=31         n=32            n=28              n=26</td></tr><tr><td colspan="1" rowspan="1">Syphilis</td><td colspan="1" rowspan="1">19</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">16</td></tr><tr><td colspan="1" rowspan="1">Hepatitis C virus (HCV)</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="4" rowspan="1">Other conditions                               n=24          n=25           n=25</td><td colspan="1" rowspan="1">n=25</td></tr><tr><td colspan="1" rowspan="1">Thrombocytopenia</td><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">Pre-eclampsia</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td></tr></table>

The method comparison results between the new devices and the predicates are shown below:

# B2GPI IgA:

# Indeterminate B2GPI IgA Samples Called Positive

<table><tr><td rowspan=2 colspan=2>N=328 (Disease-associated: 153, Suspecteddiagnosis: 50, Disease control: 125)</td><td rowspan=1 colspan=2>QuantaLiteβ2GP1IgA ELISA(SAU)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative: ≤20</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgA AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive:≥20</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>88</td></tr><tr><td rowspan=1 colspan=1>Negative:&lt;20</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>211</td><td rowspan=1 colspan=1>240</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>328</td></tr></table>

Positive percent agreement: $7 4 . 8 \%$ (86/115) 95% CI: $6 5 . 7 \% - 8 2 . 2 \%$ Negative percent agreement: $9 9 . 1 \%$ (211/213) 95% CI: 96.3% - 99.8% Total percent agreement: $9 0 . 5 \%$ (297/328) 95% CI: $8 7 . 7 \% - 9 3 . 4 \%$

# Indeterminate B2GPI IgA Samples Called Negative

<table><tr><td rowspan=2 colspan=2>N=328 (Disease-associated: 153, Suspecteddiagnosis: 50, Disease control: 125)</td><td rowspan=1 colspan=2>QuantaLiteβ2GP1IgA ELISA(SAU)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative:≤20</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgA AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive: ≥25</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>84</td></tr><tr><td rowspan=1 colspan=1>Negative:&lt;25</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>244</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>213</td><td rowspan=1 colspan=1>328</td></tr></table>

Positive percent agreement: $7 3 . 0 \%$ (84/115) $9 5 \%$ CI: 63.8% - 80.7% Negative percent agreement: $1 0 0 . 0 \%$ (213/213) 95% CI: 97.8% - 100.0%

# B2GPI IgG:

# Indeterminate B2GPI IgG Samples Called Positive

<table><tr><td rowspan=2 colspan=2>N=338 (Disease-associated: 154, Suspecteddiagnosis: 52 , Disease control: 132)</td><td rowspan=1 colspan=2>QuantaLiteβ2GP1IgG ELISA (SGU)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative: ≤20</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgG AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive:≥20</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>85</td></tr><tr><td rowspan=1 colspan=1>Negative:&lt;20</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>253</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>261</td><td rowspan=1 colspan=1>338</td></tr></table>

Positive percent agreement: $8 3 . 1 \%$ (64/77) $9 5 \%$ CI: $7 2 . 5 \% - 9 0 . 4 \%$ Negative percent agreement: $9 2 . 0 \%$ (240/261) 95% CI: 87.8% - 94.8% Total percent agreement: $8 9 . 9 \%$ (304/338) 95% CI: 86.2% - 92.8%

# Indeterminate B2GPI IgG Samples Called Negative

<table><tr><td rowspan=2 colspan=2>N=338 (Disease-associated: 154, Suspecteddiagnosis: 52, Disease control: 132)</td><td rowspan=1 colspan=2>QuantaLiteβ2GP1IgG ELISA (SGU)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative:≤20</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgG AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive: ≥25</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>78</td></tr><tr><td rowspan=1 colspan=1>Negative: &lt;25</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>246</td><td rowspan=1 colspan=1>260</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>261</td><td rowspan=1 colspan=1>338</td></tr></table>

Positive percent agreement: $8 1 . 8 \%$ (63/77) 95% CI: $7 1 . 0 \% - 8 9 . 4 \%$ Negative percent agreement: $9 4 . 3 \%$ (246/261) 95% CI: 90.5% - 96.6% Total percent agreement: $9 1 . 4 \%$ (309/338) 95% CI : 87.8% - 94.0%

# B2GPI IgM:

# Indeterminate B2GPI IgM Samples Called Positive

<table><tr><td rowspan=2 colspan=2>N=355 (Disease-associated: 169, Suspecteddiagnosis: 52 , Disease control: 134)</td><td rowspan=1 colspan=2>QuantaLite β2GP1IgM ELISA (SMU)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative: ≤20</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgM AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive:≥20</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>112</td></tr><tr><td rowspan=1 colspan=1>Negative:&lt;20</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>233</td><td rowspan=1 colspan=1>243</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>355</td></tr></table>

Positive percent agreement: $9 1 . 7 \%$ (110/120) $9 5 \%$ CI: 84.8% - 95.7%

Negative percent agreement: $9 9 . 1 \%$ (233/235) $9 5 \%$ CI: $9 6 . 7 \% - 9 9 . 9 \%$ Total percent agreement: $9 6 . 6 \%$ (343/355) $9 5 \%$ CI: 94.3% - 98.4%

# Indeterminate B2GPI IgM Samples Called Negative

<table><tr><td rowspan=2 colspan=2>N=355 (Disease-associated: 169, Suspecteddiagnosis: 52, Disease control: 134)</td><td rowspan=1 colspan=2>QuantaLite β2GP1IgM ELISA (SMU)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative:≤20</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgM AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive: ≥25</td><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>111</td></tr><tr><td rowspan=1 colspan=1>Negative: &lt;25</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>233</td><td rowspan=1 colspan=1>244</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>235</td><td rowspan=1 colspan=1>355</td></tr></table>

Positive percent agreement: $9 0 . 8 \%$ (109/120) 95% CI: 83.8% - 95.1% Negative percent agreement: $9 9 . 1 \%$ (233/235) 95% CI: 96.7% - 99.9% Total percent agreement: $9 6 . 3 \%$ (342/355) 95% CI : 94.0% - 98.2%

# B2GPI IgA/IgG/IgM results

<table><tr><td rowspan=2 colspan=2>N=331 (Disease-associated: 176, Suspecteddiagnosis: 48 , Disease control: 107)</td><td rowspan=1 colspan=2>QuantaLite β2GP1IgA/IgG/IgM (SMU)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive: &gt;20</td><td rowspan=1 colspan=1>Negative: ≤20</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgM AntibodyELISA (EU/mL)</td><td rowspan=1 colspan=1>Positive:≥20</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>147</td></tr><tr><td rowspan=1 colspan=1>Negative:&lt;20</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>184</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>177</td><td rowspan=1 colspan=1>154</td><td rowspan=1 colspan=1>331</td></tr></table>

Positive percent agreement: $8 0 . 2 \%$ (142/177) $9 5 \%$ CI: $7 3 . 4 \% - 8 5 . 7 \%$ Negative percent agreement: $9 6 . 8 \%$ (149/154) 95% CI: 92.2% - 98.8% Total percent agreement: $8 7 . 9 \%$ (291/331) 95% CI: 83.8% - 91.1%

b. Matrix comparison:

Not applicable since human serum is the only claimed specimen matrix.

3. Clinical studies:

a. Clinical sensitivity and specificity:

Serum samples from cohorts of patients with the target condition(s) or other autoimmune and infectious conditions expected to be found in the intended use population were tested and each assay performance was assessed against the clinical diagnosis.

The samples used in the clinical study for the β2-GP1 IgA, β2-GP1 IgG, β2-GP1 IgM and $\beta 2 \cdot$ GP1 $\mathrm { I g A / I g G / I g M }$ are shown in the table below:

<table><tr><td></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">E</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">ImmuLisaTM B2GP1 Antibody ELISAs</td><td colspan="1" rowspan="1">B2GP1IgA</td><td colspan="1" rowspan="1">B2GP1IgG</td><td colspan="1" rowspan="1">B2GP1IgM</td><td colspan="1" rowspan="1">B2GP1IgA/IgG/IgM</td></tr><tr><td colspan="5" rowspan="1">Number and type of clinical samples tested on each ImmuLisaTM B2GP1 Antibody ELISA</td></tr><tr><td colspan="5" rowspan="1">Disease-associated population                 n= 294      n=318       n= 345        n= 266</td></tr><tr><td colspan="1" rowspan="1">Antiphospholipid syndrome (APS)</td><td colspan="1" rowspan="1">128</td><td colspan="1" rowspan="1">97</td><td colspan="1" rowspan="1">145</td><td colspan="1" rowspan="1">105</td></tr><tr><td colspan="1" rowspan="1">Systemic lupus erythematosus (SLE)</td><td colspan="1" rowspan="1">64</td><td colspan="1" rowspan="1">98</td><td colspan="1" rowspan="1">101</td><td colspan="1" rowspan="1">61</td></tr><tr><td colspan="1" rowspan="1">APS with SLE</td><td colspan="1" rowspan="1">103</td><td colspan="1" rowspan="1">123</td><td colspan="1" rowspan="1">99</td><td colspan="1" rowspan="1">100</td></tr><tr><td colspan="1" rowspan="2">Suspected diagnosis</td><td colspan="1" rowspan="1">n= 259</td><td colspan="1" rowspan="1">n= 259</td><td colspan="2" rowspan="2">n= 259        n= 259</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Suspected diagnosis of APS</td><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">88</td><td colspan="1" rowspan="1">85</td></tr><tr><td colspan="1" rowspan="1">Suspected diagnosis of SLE</td><td colspan="1" rowspan="1">171</td><td colspan="1" rowspan="1">171</td><td colspan="1" rowspan="1">171</td><td colspan="1" rowspan="1">171</td></tr><tr><td colspan="5" rowspan="1">Disease controls                                     n= 438      n= 442       n= 432        n= 432</td></tr><tr><td colspan="1" rowspan="1">Autoimmune conditions</td><td colspan="1" rowspan="1">n=301</td><td colspan="1" rowspan="1">n=305</td><td colspan="1" rowspan="1">n= 295</td><td colspan="1" rowspan="1">n= 298</td></tr><tr><td colspan="1" rowspan="1">Celiac</td><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">22</td></tr><tr><td colspan="1" rowspan="1">Polymyositis</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">17</td></tr><tr><td colspan="1" rowspan="1">Dermatomyositis</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">Rheumatoid Arthritis</td><td colspan="1" rowspan="1">46</td><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">60</td><td colspan="1" rowspan="1">45</td></tr><tr><td colspan="1" rowspan="1">Systemic Sclerosis</td><td colspan="1" rowspan="1">31</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">23</td></tr><tr><td colspan="1" rowspan="1">Sjögren's</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">37</td><td colspan="1" rowspan="1">37</td></tr><tr><td colspan="1" rowspan="1">Wegener's granulomatosus</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">45</td><td colspan="1" rowspan="1">45</td></tr><tr><td colspan="1" rowspan="1">Churg-Strauss</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">23</td><td colspan="1" rowspan="1">23</td></tr><tr><td colspan="1" rowspan="1">Ulcerative Colitis</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">Crohn's</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">Graves' Disease</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">Hashimoto's Disease</td><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">Sensory Neuronal Hearing Loss</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">7</td></tr><tr><td colspan="1" rowspan="1">Infectious diseases</td><td colspan="1" rowspan="1">n= 102</td><td colspan="1" rowspan="1">n=102</td><td colspan="2" rowspan="1">n= 102      n=99</td></tr><tr><td colspan="1" rowspan="1">Syphilis</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">40</td><td colspan="1" rowspan="1">37</td></tr><tr><td colspan="1" rowspan="1">Hepatitis C virus (HCV)</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">12</td></tr><tr><td colspan="1" rowspan="1">HCV</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">Toxoplasma</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus (CMV)</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">Rubella</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td></tr><tr><td colspan="1" rowspan="1">Other conditions</td><td colspan="1" rowspan="1">n= 124</td><td colspan="1" rowspan="1">n= 124</td><td colspan="1" rowspan="1">n= 124</td><td colspan="1" rowspan="1">n= 124</td></tr><tr><td colspan="1" rowspan="1">Thrombocytopenia</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td></tr><tr><td colspan="1" rowspan="1">Pre-eclampsia</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">Stroke</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td></tr><tr><td colspan="1" rowspan="1">Epilepsy</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">14</td></tr><tr><td colspan="1" rowspan="1">Arterial thrombosis</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td></tr><tr><td colspan="1" rowspan="1">Venous thrombosis</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td></tr><tr><td colspan="1" rowspan="1">Myocardial infarction</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td><td colspan="1" rowspan="1">20</td></tr><tr><td colspan="1" rowspan="1">Acute coronary syndrome</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">10</td></tr></table>

The clinical study results are tabulated below:

# B2GP1 IgA:

# Results Where Indeterminate Samples Called Positive

<table><tr><td rowspan=2 colspan=2>N=653 (Disease-associated: 128 , Diseasecontrol: 525)</td><td rowspan=1 colspan=2>APS Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgA Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>49</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>91</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>483</td><td rowspan=1 colspan=1>562</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>525</td><td rowspan=1 colspan=1>653</td></tr></table>

Clinical sensitivity: 38.3% (49/128) 95% CI: $3 0 . 0 \% - 4 7 . 3 \%$ Clinical specificity: 92.0% (483/525) 95% CI: 89.3% - 94.1%

<table><tr><td rowspan=2 colspan=2>N=628 (Disease-associated: 103, Diseasecontrol: 525)</td><td rowspan=1 colspan=2>APS with SLEDiagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgA Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>483</td><td rowspan=1 colspan=1>566</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>525</td><td rowspan=1 colspan=1>628</td></tr></table>

Clinical sensitivity: 19.4% (20/103) 95% CI: 12.5% - 28.6% Clinical specificity: 92.0% (483/525) 95% CI: 89.3% - 94.1%

<table><tr><td rowspan=2 colspan=2>N=589 (Disease-associated: 64, Diseasecontrol: 525)</td><td rowspan=1 colspan=2>SLE Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgA Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>49</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>483</td><td rowspan=1 colspan=1>540</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>525</td><td rowspan=1 colspan=1>589</td></tr></table>

Clinical sensitivity: 10.9% (7/64) 95% CI: $4 . 9 \% - 2 1 . 8 \%$ Clinical specificity: 92.0% (483/525) 95% CI: 89.3% - 94.1%

# Results Where Indeterminate Samples Called Negative

<table><tr><td rowspan="2">N=653 (Disease-associated: 128 , Disease control: 525)</td><td colspan="2">APS Diagnosis</td><td rowspan="2">Total</td></tr><tr><td>Positive</td><td>Negative</td></tr></table>

<table><tr><td colspan="2"></td><td></td><td></td><td></td></tr><tr><td rowspan="2">ImmuLisa EnhancedTM B2GPI IgA Antibody ELISA</td><td>Positive</td><td>47</td><td>30</td><td>77</td></tr><tr><td>Negative</td><td>81</td><td>495</td><td>576</td></tr><tr><td colspan="2"></td><td>128</td><td>525</td><td>653</td></tr></table>

Clinical sensitivity: $3 6 . 7 \%$ (49/128) 95% CI: 28.5% - 47.5% Clinical specificity: $9 4 . 3 \%$ (583/525) 95% CI: 91.9% - 96.0%

<table><tr><td rowspan=2 colspan=2>N=628 (Disease-associated: 103, Diseasecontrol: 525)</td><td rowspan=1 colspan=2>APS with SLEDiagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgA Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>47</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>495</td><td rowspan=1 colspan=1>581</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>103</td><td rowspan=1 colspan=1>525</td><td rowspan=1 colspan=1>628</td></tr></table>

Clinical sensitivity: 16.5% (17/103) 95% CI: $1 0 . 2 \% - 2 5 . 4 \%$ Clinical specificity: 94.3% (583/525) 95% CI: 91.9% - 96.0%

<table><tr><td rowspan=2 colspan=2>N=589 (Disease-associated: 64, Diseasecontrol: 525)</td><td rowspan=1 colspan=2>SLE Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgA Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>495</td><td rowspan=1 colspan=1>553</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>525</td><td rowspan=1 colspan=1>589</td></tr></table>

Clinical sensitivity: 9.4% (6/64) $9 5 \%$ CI: $3 . 9 \% - 1 9 . 9 \%$ Clinical specificity: 94.3% (583/525) 95% CI: $9 1 . 9 \% - 9 6 . 0 \%$

# B2GP1 IgG:

# Indeterminate B2GPI IgG Samples Called Positive

<table><tr><td rowspan=2 colspan=2>N=617 (Disease-associated: 97, Diseasecontrol: 520)</td><td rowspan=1 colspan=2>APS Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgG Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>89</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>488</td><td rowspan=1 colspan=1>528</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>520</td><td rowspan=1 colspan=1>617</td></tr></table>

Clinical sensitivity: 58.8% (57/97) 95% CI: 48.3 - 68.5% Clinical specificity: 93.8% (488/520) 95% CI: 91.3 - 95.7%

<table><tr><td>N=643 (Disease-associated: 123, Disease control: 520)</td><td>APS with SLE Diagnosis</td><td>Total</td></tr></table>

<table><tr><td></td><td></td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgG Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>103</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>488</td><td rowspan=1 colspan=1>540</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>520</td><td rowspan=1 colspan=1>643</td></tr></table>

Clinical sensitivity: 57.7% (71/123) 95% CI: $4 8 . 5 \% - 6 6 . 5 \%$ Clinical specificity: 93.8% (488/520) 95% CI: 92% - 96%

<table><tr><td rowspan=2 colspan=2>N=618 (Disease-associated: 98, Disease control:520)</td><td rowspan=1 colspan=2>SLE Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgG Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>58</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>488</td><td rowspan=1 colspan=1>560</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>520</td><td rowspan=1 colspan=1>618</td></tr></table>

Clinical sensitivity: 26.5% (26/98) 95% CI: 18.4% - 36.6% Clinical specificity: 93.8% (488/520) 95% CI: 91.3% - 95.7%

# Indeterminate B2GPI IgG Samples Called Negative

<table><tr><td rowspan=2 colspan=2>N=617 (Disease-associated: 97, Diseasecontrol: 520)</td><td rowspan=1 colspan=2>APS Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgG Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>78</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>495</td><td rowspan=1 colspan=1>539</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>97</td><td rowspan=1 colspan=1>520</td><td rowspan=1 colspan=1>617</td></tr></table>

Clinical sensitivity: 54.6% (53/97) 95% CI: 44.2 - 64.7% Clinical specificity: 95.2% (495/520) 95% CI: 92.9 - 96.8%

<table><tr><td rowspan=2 colspan=2>N=643 (Disease-associated: 123, Diseasecontrol: 520)</td><td rowspan=1 colspan=2>APS with SLEDiagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgG Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>89</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>495</td><td rowspan=1 colspan=1>554</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>520</td><td rowspan=1 colspan=1>643</td></tr></table>

Clinical sensitivity: 52.0% (64/123) 95% CI: 42.9% - 61.1% Clinical specificity: 95.2% (495/520) 95% CI: 92.9 - 96.8%

<table><tr><td colspan="2" rowspan="2">N=618 (Disease-associated: 98, Disease control:520)</td><td colspan="2" rowspan="1">SLE Diagnosis</td><td colspan="1" rowspan="2">Total</td></tr><tr><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">ImmuLisa EnhancedTM</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">21</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">46</td></tr><tr><td colspan="1" rowspan="1">B2GPI IgG Antibody ELISA</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">77</td><td colspan="1" rowspan="1">495</td><td colspan="1" rowspan="1">572</td></tr><tr><td colspan="2" rowspan="1">Total</td><td colspan="1" rowspan="1">98</td><td colspan="1" rowspan="1">520</td><td colspan="1" rowspan="1">618</td></tr></table>

Clinical sensitivity: $2 1 . 4 \%$ (21/98) 95% CI: 14.0% - 31.1% Clinical specificity: $9 5 . 2 \%$ (495/520) 95% CI: 92.9 - 96.8%

# B2GP1 IgM:

# Indeterminate B2GPI IgM Samples Called Positive

<table><tr><td rowspan=2 colspan=2>N=655 (Disease-associated: 145 , Diseasecontrol: 510)</td><td rowspan=1 colspan=2>APS Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgM Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>93</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>113</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>490</td><td rowspan=1 colspan=1>542</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>145</td><td rowspan=1 colspan=1>510</td><td rowspan=1 colspan=1>655</td></tr></table>

Clinical sensitivity: 64.1% (93/145) 95% CI: 55.7- 71.8% Clinical specificity: 96.1% (490/510) 95% CI: 93.9 - 97.5%

<table><tr><td colspan="2" rowspan="2">N=609 (Disease-associated: 99, Disease control: 510)</td><td colspan="2">APS with SLE Diagnosis</td><td rowspan="2">Total</td></tr><tr><td>Positive</td><td>Negative</td></tr><tr><td rowspan="2">ImmuLisa EnhancedTM</td><td>Positive</td><td>46</td><td>20</td><td>66</td></tr><tr><td>Negative</td><td>53</td><td>490</td><td>543</td></tr><tr><td>B2GPI IgM Antibody ELISA</td><td>Total</td><td>99</td><td>510</td><td>609</td></tr></table>

Clinical sensitivity: 46.5% (46/99) 95% CI: 36.5 - 56.7% Clinical specificity: 96.1% (490/510) 95% CI: 93.9 - 97.5%

<table><tr><td rowspan=2 colspan=2>N=673 (Disease-associated: 101, Diseasecontrol: 510)</td><td rowspan=1 colspan=2>SLE Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgM Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>39</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>490</td><td rowspan=1 colspan=1>572</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>510</td><td rowspan=1 colspan=1>611</td></tr></table>

Clinical sensitivity: 18.8% (19/101) 95% CI: 12.0 - 28.1% Clinical specificity: 96.1% (490/510) 95% CI: 93.9 - 97.5%

# Indeterminate B2GPI IgM Samples Called Negative

<table><tr><td rowspan=2 colspan=2>N=655 (Disease-associated: 145 , Diseasecontrol: 510)</td><td rowspan=1 colspan=2>APS Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgM Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>102</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>497</td><td rowspan=1 colspan=1>553</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>145</td><td rowspan=1 colspan=1>510</td><td rowspan=1 colspan=1>655</td></tr></table>

Clinical sensitivity: 61.4% (89/145) 95% CI: 52.9- 69.2% Clinical specificity: 97.5% (497/510) 95% CI: 95.6 - 98.6%

<table><tr><td rowspan=2 colspan=2>N=609 (Disease-associated: 99, Disease control:510)</td><td rowspan=1 colspan=2>APS with SLEDiagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgM Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>55</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>497</td><td rowspan=1 colspan=1>554</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>510</td><td rowspan=1 colspan=1>609</td></tr></table>

Clinical sensitivity: 42.4% (42/99) 95% CI: 32.7 - 52.8% Clinical specificity: 97.5% (497/510) 95% CI: 95.6 - 98.6%

<table><tr><td rowspan=2 colspan=2>N=673 (Disease-associated: 101, Diseasecontrol: 510)</td><td rowspan=1 colspan=2>SLE Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgM Antibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>29</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>497</td><td rowspan=1 colspan=1>582</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>510</td><td rowspan=1 colspan=1>611</td></tr></table>

Clinical sensitivity: 15.8% (16/101) 95% CI: 9.6 - 24.8% Clinical specificity: 97.5% (497/510) 95% CI: 95.6 - 98.6%

# B2GP1 IgA/IgG/IgM:

<table><tr><td rowspan=2 colspan=2>N=623 (Disease-associated: 105, Diseasecontrol: 518)</td><td rowspan=1 colspan=2>APS Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgA/IgG/IgMAntibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>131</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>476</td><td rowspan=1 colspan=1>492</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>105</td><td rowspan=1 colspan=1>518</td><td rowspan=1 colspan=1>623</td></tr></table>

Clinical sensitivity: 84.8% (89/105) 95% CI: 76.1 - 90.8% Clinical specificity: 91.9% (476/518) 95% CI: 89.1 - 94.0%

<table><tr><td rowspan="2">N=618 (Disease-associated: 100 , Disease control: 518)</td><td colspan="2">APS with SLE Diagnosis</td><td rowspan="2">Total</td></tr><tr><td>Positive</td><td>Negative</td></tr></table>

<table><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgA/IgG/IgMAntibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>108</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>476</td><td rowspan=1 colspan=1>510</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>518</td><td rowspan=1 colspan=1>618</td></tr></table>

Clinical sensitivity: $6 6 . 0 \%$ (66/100) 95% CI: 55.8 - 75.0% Clinical specificity: $9 1 . 9 \%$ (476/518) 95% CI: 89.1 - 94.0%

<table><tr><td rowspan=2 colspan=2>N=579 (Disease-associated: 61 , Disease control:518)</td><td rowspan=1 colspan=2>SLE Diagnosis</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=2 colspan=1>ImmuLisa EnhancedTMB2GPI IgA/IgG/IgMAntibody ELISA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>57</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>476</td><td rowspan=1 colspan=1>522</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>518</td><td rowspan=1 colspan=1>579</td></tr></table>

Clinical sensitivity: 24.6% (15/61) 95% CI: 14.8 - 37.6% Clinical specificity: 91.9% (476/518) 95% CI: 89.1 - 94.0%

4. Clinical cut-off:

Not applicable

# 5. Expected values/Reference range:

Test results in a normal population are expected to be negative. A study of 174 normal, apparently disease-free samples tested with the B2GP1 IgA assay yielded seven positive results $( 4 . 0 \% )$ . A study of 151 normal, apparently disease-free samples tested with the B2GP1 IgG yielded five positive results $( 3 . 3 \% )$ . A study of 151 normal, apparently disease-free samples tested with the B2GP1 IgM assay yielded three positive results $( 2 . 0 \% )$ . A study of 206 normal, apparently disease-free samples tested with the B2GP1 $\mathrm { I g A / I g G / I g M }$ assay yielded seven positive results $( 3 . 4 \% )$ .

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.